Prostate cancer vaccine - NewLink Genetics

Drug Profile

Prostate cancer vaccine - NewLink Genetics

Alternative Names: HyperAcute Prostate

Latest Information Update: 19 Dec 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Prostate cancer

Most Recent Events

  • 13 Dec 2012 Final efficacy, adverse events, pharmacodynamics and immunogenicity data from a phase I/II trial in Prostate cancer released by NewLink Genetics Corporation
  • 22 May 2008 Immunogenicity data from a phase I/II trial in hormone-refractory Prostate cancer presented at the 103rd Annual Meeting of the American Urological Association (AUA-2008)
  • 31 Mar 2005 Phase-I/II clinical trials in Prostate cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top